MAPT and dementia: This includes the use of biomarkers such as assessing hippocampal atrophy using magnetic resonance imaging or decreased levels of Aβ42 and elevated levels of tau and phosphor-tau in cerebrospinal fluid in preclinical stages of dementia [7, 8].